These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 9835539)
1. In vitro activities of membrane-active peptides against gram-positive and gram-negative aerobic bacteria. Giacometti A; Cirioni O; Greganti G; Quarta M; Scalise G Antimicrob Agents Chemother; 1998 Dec; 42(12):3320-4. PubMed ID: 9835539 [TBL] [Abstract][Full Text] [Related]
2. In vitro susceptibility tests for cationic peptides: comparison of broth microdilution methods for bacteria that grow aerobically. Giacometti A; Cirioni O; Barchiesi F; Del Prete MS; Fortuna M; Caselli F; Scalise G Antimicrob Agents Chemother; 2000 Jun; 44(6):1694-6. PubMed ID: 10817731 [TBL] [Abstract][Full Text] [Related]
3. Combination studies between polycationic peptides and clinically used antibiotics against Gram-positive and Gram-negative bacteria. Giacometti A; Cirioni O; Del Prete MS; Paggi AM; D'Errico MM; Scalise G Peptides; 2000 Aug; 21(8):1155-60. PubMed ID: 11035200 [TBL] [Abstract][Full Text] [Related]
4. Antimicrobial activity of polycationic peptides. Giacometti A; Cirioni O; Barchiesi F; Del Prete MS; Scalise G Peptides; 1999 Nov; 20(11):1265-73. PubMed ID: 10612440 [TBL] [Abstract][Full Text] [Related]
5. In-vitro activity of cationic peptides alone and in combination with clinically used antimicrobial agents against Pseudomonas aeruginosa. Giacometti A; Cirioni O; Barchiesi F; Fortuna M; Scalise G J Antimicrob Chemother; 1999 Nov; 44(5):641-5. PubMed ID: 10552980 [TBL] [Abstract][Full Text] [Related]
6. In vitro activities of polycationic peptides alone and in combination with clinically used antimicrobial agents against Rhodococcus equi. Giacometti A; Cirioni O; Ancarani F; Del Prete MS; Fortuna M; Scalise G Antimicrob Agents Chemother; 1999 Aug; 43(8):2093-6. PubMed ID: 10428947 [TBL] [Abstract][Full Text] [Related]
7. Killing of Fusobacterium nucleatum, Porphyromonas gingivalis and Prevotella intermedia by protegrins. Miyasaki KT; Iofel R; Oren A; Huynh T; Lehrer RI J Periodontal Res; 1998 Feb; 33(2):91-8. PubMed ID: 9553868 [TBL] [Abstract][Full Text] [Related]
8. In-vitro activity of lytic peptides alone and in combination with macrolides and inhibitors of dihydrofolate reductase against Pneumocystis carinii. Cirioni O; Giacometti A; Barchiesi F; Scalise G J Antimicrob Chemother; 1998 Oct; 42(4):445-51. PubMed ID: 9818742 [TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activity of imipenem against gram-positive and gram-negative aerobic bacteria from clinical isolates. Bastianini L; Sposini T; Bartoli A; Marconi P Microbiologica; 1988 Apr; 11(2):137-42. PubMed ID: 3165489 [TBL] [Abstract][Full Text] [Related]
10. In vitro anticryptosporidial activity of ranalexin alone and in combination with other peptides and with hydrophobic antibiotics. Giacometti A; Cirioni O; Barchiesi F; Fortuna M; Scalise G Eur J Clin Microbiol Infect Dis; 1999 Nov; 18(11):827-9. PubMed ID: 10614961 [TBL] [Abstract][Full Text] [Related]
11. In-vitro activity of polycationic peptides against Cryptosporidium parvum, Pneumocystis carinii and yeast clinical isolates. Giacometti A; Cirioni O; Barchiesi F; Caselli F; Scalise G J Antimicrob Chemother; 1999 Sep; 44(3):403-6. PubMed ID: 10511411 [TBL] [Abstract][Full Text] [Related]
12. A novel tool against multiresistant bacterial pathogens: lipopeptide modification of the natural antimicrobial peptide ranalexin for enhanced antimicrobial activity and improved pharmacokinetics. Domhan C; Uhl P; Meinhardt A; Zimmermann S; Kleist C; Lindner T; Leotta K; Mier W; Wink M Int J Antimicrob Agents; 2018 Jul; 52(1):52-62. PubMed ID: 29649587 [TBL] [Abstract][Full Text] [Related]
13. Development of Amphipathic Antimicrobial Peptide Foldamers Based on Magainin 2 Sequence. Goto C; Hirano M; Hayashi K; Kikuchi Y; Hara-Kudo Y; Misawa T; Demizu Y ChemMedChem; 2019 Nov; 14(22):1911-1916. PubMed ID: 31667994 [TBL] [Abstract][Full Text] [Related]
14. Bacteria-selective synergism between the antimicrobial peptides alpha-helical magainin 2 and cyclic beta-sheet tachyplesin I: toward cocktail therapy. Kobayashi S; Hirakura Y; Matsuzaki K Biochemistry; 2001 Dec; 40(48):14330-5. PubMed ID: 11724544 [TBL] [Abstract][Full Text] [Related]
15. In vitro activities of membrane-active peptides alone and in combination with clinically used antimicrobial agents against Stenotrophomonas maltophilia. Giacometti A; Cirioni O; Del Prete MS; Barchiesi F; Fortuna M; Drenaggi D; Scalise G Antimicrob Agents Chemother; 2000 Jun; 44(6):1716-9. PubMed ID: 10817738 [TBL] [Abstract][Full Text] [Related]
16. In vitro activity of MDL 62,879 (GE2270 A) against aerobic gram-positive and anaerobic bacteria. King A; Bethune L; Phillips I Antimicrob Agents Chemother; 1993 Apr; 37(4):746-9. PubMed ID: 8494370 [TBL] [Abstract][Full Text] [Related]
17. A novel polycationic analogue of gratisin with antibiotic activity against both Gram-positive and Gram-negative bacteria. Tamaki M; Kokuno M; Suzuki Y; Iwama M; Shindo M; Uchida Y J Antibiot (Tokyo); 2008 Jan; 61(1):33-5. PubMed ID: 18305357 [TBL] [Abstract][Full Text] [Related]
18. Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates. Butler MM; Williams JD; Peet NP; Moir DT; Panchal RG; Bavari S; Shinabarger DL; Bowlin TL Antimicrob Agents Chemother; 2010 Sep; 54(9):3974-7. PubMed ID: 20625154 [TBL] [Abstract][Full Text] [Related]
19. In vitro activity of A-16686, a new glycopeptide. Neu HC; Neu NM Chemotherapy; 1986; 32(5):453-7. PubMed ID: 3757587 [TBL] [Abstract][Full Text] [Related]